Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen.

Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen.

CAMPATH-1 antibodies recognise a unique molecule on human lymphocytes and are unusually efficient at causing cell lysis with homologous complement. They have been successfully used for lymphocyte depletion in vivo in a variety of diseases. The antigen is a small glycosylphosphatidylinositol (GPI)-an...

Bibliográfalaš dieđut
Váldodahkkit:	Xia, M, Hale, G, Waldmann, H
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	1993

Geahča maid

The CAMPATH-1 antigen (CDw52).
Dahkki: Hale, G, et al.
Almmustuhtton: (1990)

Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone.
Dahkki: Xia, M, et al.
Almmustuhtton: (1991)

Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis.
Dahkki: Xia, M, et al.
Almmustuhtton: (1993)

COMPLEMENT LYSIS MEDIATED BY ENGINEERED MULTIPLE-DOMAIN FORMS OF THE THERAPEUTIC ANTIBODY CAMPATH-1H
Dahkki: Greenwood, J, et al.
Almmustuhtton: (1994)

Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies.
Dahkki: Bindon, C, et al.
Almmustuhtton: (1988)

Engineering multiple-domain forms of the therapeutic antibody CAMPATH-1H: effects on complement lysis.
Dahkki: Greenwood, J, et al.
Almmustuhtton: (1994)

Therapeutic potential of monoclonal antibodies to the leukocyte-common antigen. Synergy and interference in complement-mediated lysis.
Dahkki: Bindon, C, et al.
Almmustuhtton: (1985)

Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
Dahkki: Williams, R, et al.
Almmustuhtton: (2000)

Peripheral blood dendritic cells express CD52 and are depleted in-vivo by treatment with CAMPATH-1H.
Dahkki: Buggins, A, et al.
Almmustuhtton: (2001)

Specificity of monoclonal antibody Campath-1.
Dahkki: Hale, G, et al.
Almmustuhtton: (1988)

CAMPATH: from concept to clinic.
Dahkki: Waldmann, H, et al.
Almmustuhtton: (2005)

Pilot study of CAMPATH-1, a rat monoclonal antibody that fixes human complement, as an immunosuppressant in organ transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (1986)

Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart.
Dahkki: Cheetham, G, et al.
Almmustuhtton: (1998)

Availability of Campath-1 antibodies for bone marrow transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (1995)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (1994)

T cell depletion with CAMPATH-1 in allogeneic bone marrow transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (1988)

CAMPATH-1H in inflammatory arthritis.
Dahkki: Watts, R, et al.
Almmustuhtton: (1993)

Synergistic complement lysis by monoclonal antibodies to the human leukocyte common antigen requires both the classical and alternative pathways.
Dahkki: Bindon, C, et al.
Almmustuhtton: (1987)

1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen.
Dahkki: James, L, et al.
Almmustuhtton: (1999)

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
Dahkki: Hale, G, et al.
Almmustuhtton: (1996)

CAMPATH-1 antibodies in stem-cell transplantation.
Dahkki: Hale, G, et al.
Almmustuhtton: (2001)

Leukaemic relapse after Campath 1-treated bone-marrow transplantation for leukaemia.
Dahkki: Waldmann, H, et al.
Almmustuhtton: (1987)

CAMPATH-1 MOAB IN THE TREATMENT OF REFRACTORY AUTOIMMUNE THROMBOCYTOPENIC PURPURA (ATP)
Dahkki: Lim, S, et al.
Almmustuhtton: (1993)

Campath-1 Abs 'in the bag' for hematological malignancies: the Cape Town experience.
Dahkki: Novitzky, N, et al.
Almmustuhtton: (2004)

CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura.
Dahkki: Lim, S, et al.
Almmustuhtton: (1993)

TREATMENT OF RHEUMATOID-ARTHRITIS WITH HUMANIZED ANTILYMPHOCYTE ANTIBODY CAMPATH-1H
Dahkki: Watts, R, et al.
Almmustuhtton: (1992)

ISOTYPE VARIANTS OF CAMPATH-1 ANTIBODY - REQUIREMENTS FOR EFFECTIVE ANTIBODY ACTION INVIVO
Dahkki: Dyer, M, et al.
Almmustuhtton: (1989)

Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H.
Dahkki: Newman, D, et al.
Almmustuhtton: (1995)

Campath-1H therapy in refractory ocular inflammatory disease.
Dahkki: Dick, A, et al.
Almmustuhtton: (2000)

A personal history of the CAMPATH-1H antibody.
Dahkki: Waldmann, H
Almmustuhtton: (2002)

Sustained remission of severe resistant autoimmune neutropenia with Campath-1H.
Dahkki: Killick, S, et al.
Almmustuhtton: (1997)

CAMPATH-1 FOLLOWING RENAL-TRANSPLANTATION - A RANDOMIZED TRIAL
Dahkki: Friend, P, et al.
Almmustuhtton: (1988)

Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?
Dahkki: Chakrabarti, S, et al.
Almmustuhtton: (2004)

Alemtuzumab (Campath-1H) for treatment of lymphoid malignancies in the age of nonmyeloablative conditioning?
Dahkki: Hale, G, et al.
Almmustuhtton: (2002)

T-CELL DEPLETION BY EXPOSURE TO CAMPATH-1G IN-VITRO PREVENTS GRAFT-VERSUS-HOST DISEASE
Dahkki: Jacobs, P, et al.
Almmustuhtton: (1994)

Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H.
Dahkki: Isaacs, J, et al.
Almmustuhtton: (1996)

Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype.
Dahkki: Dyer, M, et al.
Almmustuhtton: (1989)

REMISSION INDUCTION IN PATIENTS WITH LYMPHOID MALIGNANCIES USING UNCONJUGATED CAMPATH-1 MONOCLONAL-ANTIBODIES
Dahkki: Dyer, M, et al.
Almmustuhtton: (1990)

CAMPATH-IH in multiple sclerosis.
Dahkki: Moreau, T, et al.
Almmustuhtton: (1996)

Treatment of chronic lymphocytic leukaemia and autoimmune complications with antibody targeted to the CD52 antigen (Campath) - the first Russian experience
Dahkki: T. E. Byalik, et al.
Almmustuhtton: (2022-11-01)